187 related articles for article (PubMed ID: 27161970)
1. Use and Costs of Disease Monitoring in Women With Metastatic Breast Cancer.
Accordino MK; Wright JD; Vasan S; Neugut AI; Hillyer GC; Hu JC; Hershman DL
J Clin Oncol; 2016 Aug; 34(24):2820-6. PubMed ID: 27161970
[TBL] [Abstract][Full Text] [Related]
2. High-cost imaging in elderly patients with stage IV cancer.
Hu YY; Kwok AC; Jiang W; Taback N; Loggers ET; Ting GV; Lipsitz SR; Weeks JC; Greenberg CC
J Natl Cancer Inst; 2012 Aug; 104(15):1164-72. PubMed ID: 22851271
[TBL] [Abstract][Full Text] [Related]
3. Increased resource use in men with metastatic prostate cancer does not result in improved survival or quality of care at the end of life.
Golan R; Bernstein AN; Gu X; Dinerman BF; Sedrakyan A; Hu JC
Cancer; 2018 May; 124(10):2212-2219. PubMed ID: 29579318
[TBL] [Abstract][Full Text] [Related]
4. Tumor marker usage and medical care costs among older early-stage breast cancer survivors.
Ramsey SD; Henry NL; Gralow JR; Mirick DK; Barlow W; Etzioni R; Mummy D; Thariani R; Veenstra DL
J Clin Oncol; 2015 Jan; 33(2):149-55. PubMed ID: 25332254
[TBL] [Abstract][Full Text] [Related]
5. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
6. Guideline-Concordant Treatment Among Elderly Women With HER2-Positive Metastatic Breast Cancer in the United States.
Vyas AM; Aroke H; Kogut S
J Natl Compr Canc Netw; 2020 Apr; 18(4):405-413. PubMed ID: 32259787
[TBL] [Abstract][Full Text] [Related]
7. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer.
Di Meglio A; Lin NU; Freedman RA; Barry WT; Winer EP; Vaz-Luis I
J Natl Compr Canc Netw; 2017 Mar; 15(3):316-324. PubMed ID: 28275032
[No Abstract] [Full Text] [Related]
9. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
10. Advanced imaging and hospice use in end-of-life cancer care.
Dinan MA; Curtis LH; Setoguchi S; Cheung WY
Support Care Cancer; 2018 Oct; 26(10):3619-3625. PubMed ID: 29728843
[TBL] [Abstract][Full Text] [Related]
11. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021.
Jaber Chehayeb R; Hood A; Wang X; Miksad R; Schellhorn Mougalian S; Lustberg MB; Wang SY; Greenup RA; Pusztai L; Kunst N
JAMA Netw Open; 2022 Nov; 5(11):e2244204. PubMed ID: 36445704
[TBL] [Abstract][Full Text] [Related]
12. Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.
Bonotto M; Basile D; Gerratana L; Bartoletti M; Lisanti C; Pelizzari G; Vitale MG; Fanotto V; Poletto E; Minisini AM; Russo S; Andreetta C; Mansutti M; Fasola G; Puglisi F
Future Oncol; 2020 Sep; 16(27):2059-2073. PubMed ID: 32598185
[No Abstract] [Full Text] [Related]
13. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population.
Kruse GB; Amonkar MM; Smith G; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2008; 14(9):844-57. PubMed ID: 19006441
[TBL] [Abstract][Full Text] [Related]
14. Concordance with NCCN treatment guidelines: Relations with health care utilization, cost, and mortality in breast cancer patients with secondary metastasis.
Rocque GB; Williams CP; Kenzik KM; Jackson BE; Azuero A; Halilova KI; Ingram SA; Pisu M; Forero A; Bhatia S
Cancer; 2018 Nov; 124(21):4231-4240. PubMed ID: 30317547
[TBL] [Abstract][Full Text] [Related]
15. Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population.
Crivello ML; Ruth K; Sigurdson ER; Egleston BL; Evers K; Wong YN; Boraas M; Bleicher RJ
Ann Surg Oncol; 2013 Jan; 20(1):102-10. PubMed ID: 22878617
[TBL] [Abstract][Full Text] [Related]
16. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
17. Baseline Estimates of Adherence to American Society of Clinical Oncology/American Board of Internal Medicine Choosing Wisely Initiative Among Patients With Cancer Enrolled With a Large Regional Commercial Health Insurer.
Ramsey SD; Fedorenko C; Chauhan R; McGee R; Lyman GH; Kreizenbeck K; Bansal A
J Oncol Pract; 2015 Jul; 11(4):338-43. PubMed ID: 26060225
[TBL] [Abstract][Full Text] [Related]
18. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008-2011.
Wilson LE; Pollack CE; Greiner MA; Dinan MA
Breast Cancer Res Treat; 2018 Jul; 170(2):361-371. PubMed ID: 29536319
[TBL] [Abstract][Full Text] [Related]
19. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
20. Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer.
Saad A; Kanate A; Sehbai A; Marano G; Hobbs G; Abraham J
Clin Breast Cancer; 2008 Aug; 8(4):357-61. PubMed ID: 18757264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
